ClinicalTrials.gg
RecruitingNCT07710820Updated Jul 17, 2026

A Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers

An interventional study of 31237616 and 31237617 in Smoking and Tobacco, sponsored by RAI Services Company. Recruiting at 9 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by RAI Services Company (part of British American Tobacco) · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
1,060
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to evaluate the rate of end of study complete cigarette reduction in health adult consumers of cigarettes when given access to a heated tobacco product (HTP). The primary study objective is to evaluate the impact of access to HTP Device 1 or HTP Device 2 and a single stick variant on the rate of final 7-day abstinence from smoking cigarettes among U.S. adult smokers at the end of a 3-month study period.

Read the detailed description

This will be a multi-site, open-label, two-arm study to evaluate the rate of end of study complete combustible cigarette (CC) reduction in healthy adult consumers of CC when given access to a heated tobacco product (HTP) device (glo or glo plus), with one of four variants of HTP consumables (also known as "sticks" or "stick variants", under the brand name "virto") over a 3-month (90-day) actual use period (AUP).

02

Conditions studied

  • Smoking
  • Tobacco

Keywords

  • Tobacco Harm Reduction
  • Smoking
  • Tobacco Use
  • Tobacco Smoking
03

In context

Smoking

1,509 studies on the registry are indexed under Smoking; 193 are open to participants now.

This study's planned enrollment of 1,060 is above the median of 115 across 1,164 interventional studies indexed under Smoking.

Browse Smoking studies →

Lead sponsor

RAI Services Company is the lead sponsor of 53 studies on the registry; 12 are open to participants now.

First submitted after RAI Services Company became part of British American Tobacco.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to read, understand, and are willing to sign an Form (ICF) and complete questionnaires written in English.
  • Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent, verified with government-issued identification.
  • All female (assigned at birth) candidate participants who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant. Note: Participants who identify as "intersex" or "unknown" during screening, will be required to take a pregnancy test if they wish to take one.
  • Currently smoke at least five combustible cigarettes on smoking days in the past 30 days.
  • Smoke combustible cigarettes on 15 or more of the past 30 days.
  • Smoked at least 100 factory-made filtered menthol and/or non-menthol combustible cigarettes in their lifetime prior to the Site Enrollment Visit.
  • Must indicate a neutral/positive intention to use at least one stick variant at the Site Enrollment Visit.
  • Own a smartphone (iOS or Android) with internet access to download a study application to access surveys and the capability to receive notifications.
  • Agree to participate in the study and to abide by the study restrictions and requirements, as described in the ICF.
  • Must try all four stick variants during the 1-week product trial period.
  • Must indicate a neutral/positive intention to use at least one stick variant following the product trial period.

Exclusion criteria

Exclusion Criteria:

  • Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.
  • Male participants who self-report they are not willing to use a barrier method of (e.g., a condom with spermicide) or refrain from donating sperm from the time of the signing of the ICF until the end of the study, unless they have undergone a vasectomy or are abstinent from heterosexual intercourse, or their female partner was not able to bear children.
  • Female participants who self-report not using adequate methods to prevent pregnancy.
  • Persons with pacemakers or other embedded electronic medical devices fitted.
  • Participants who self-report having an unstable heart condition, severe hypertension, or diabetes.
  • Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
  • Participants who have used electronic nicotine delivery system (ENDS), nicotine pouches, HTP or smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products, other combustible tobacco/nicotine products, and other oral nicotine products (tablets, gums, and lozenges) on 5 or more days in the past 30 days.
  • Participants who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
  • Employee of a company that manufactures tobacco or HTPs.
  • Persons who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or HTPs.
  • Have taken part in a tobacco/nicotine research study in the past 30 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,060 participants (estimated)

Study arms

  • Active comparator
    HTP Device 1

    HTP Device (One Piece) with two menthol and two tobacco stick variants

    Other: 31237616 · Other: 31237617 · Other: 31237571 · Other: 31237581

  • Active comparator
    HTP Device 2

    HTP Device (Two Piece) with two menthol and two tobacco stick variants

    Other: 31237616 · Other: 31237617 · Other: 31237571 · Other: 31237581

Interventions

  • Other31237616

    Tobacco Flavor #1

  • Other31237617

    Tobacco Flavor #2

  • Other31237571

    Menthol #1

  • Other31237581

    Menthol #2

06

What researchers measure

Primary outcomes

  1. Number and proportion of participants self-reporting past 7-day complete combustible cigarette reduction (abstinence) during the final 7 days of the 3-month (90-day) study period in each study arm and by stick variant within the study arm.

    Time frame: 7 days

Secondary outcomes

  1. The number and proportion of participants who completely switch from combustible cigarette smoking to HTP device 1 or HTP device 2 during the entire final 7 days of the 3 month study period in each study arm and by stick variant within the study arm.

    Time frame: 7 days

  2. The number and proportion of participants who reduce their combustible cigarettes by more than or equal to 50% within their average weekly cigarettes per day from baseline to final 7 days of the study period in each study arm and by stick variant.

    Time frame: 3 months

  3. The time to first 7-day abstinence of combustible cigarettes by participants in each study arm and by stick variant within each study arm

    Time frame: 3 months

  4. The weekly mean percent cigarettes per day reductions from baseline in each study arm and by stick variant within each arm

    Time frame: 3 months

  5. The number and type of adverse experiences/events in relation to use of the Study IP in each study arm and by stick variant within each study arm

    Time frame: 3 months

07

Study locations

9 of 9 sites recruiting
  • Opinions Brandon
    Brandon, Florida 33511, United States
    Recruiting
  • Opinions Coral Springs
    Coral Springs, Florida 33071, United States
    Recruiting
  • Opinions Chicago
    Aurora, Illinois 60504, United States
    Recruiting
  • Opinions Chicago
    Gurnee, Illinois 60031, United States
    Recruiting
  • Opinions Las Vegas
    Las Vegas, Nevada 89107, United States
    Recruiting
  • Opinions Las Vegas
    Las Vegas, Nevada 89119, United States
    Recruiting
  • Opinions Fort Worth
    Fort Worth, Texas 76132, United States
    Recruiting
  • Opinions Houston
    Houston, Texas 77070, United States
    Recruiting
  • Opinions Dallas
    Hurst, Texas 76053, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710820
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 17, 2026

Study contacts

Emily Smith
Contact
smithe13@rjrt.com
336-741-2396

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion